Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 1 2Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 13Breast 9Tumor-Agnostic 6Genitourinary 5Other solid neoplasm 3CNS 3Thoracic 2Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 156Carboplatin 146Cisplatin 129Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 68Docetaxel 61Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33130-nm albumin-bound paclitaxel 26Radiosurgery 25fludarabine 23Ipilimumab 23Irinotecan 21Taxes 20Radiation 20Oxaliplatin 20Magnetic Resonance Spectroscopy 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × niraparib × Thoracic × Clear all
NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Tesaro, Inc.

Phase 1 Completed
60 enrolled 91 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03891615 2020-12-16

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Massachusetts General Hospital

Phase 1 Unknown
30 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡